Last reviewed · How we verify

Bivalirudin with and without eptifibatide

LifeBridge Health · FDA-approved active Small molecule

Bivalirudin with and without eptifibatide is a Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) Small molecule drug developed by LifeBridge Health. It is currently FDA-approved for Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.

Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects.

Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.

At a glance

Generic nameBivalirudin with and without eptifibatide
SponsorLifeBridge Health
Drug classDirect thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide)
TargetThrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Bivalirudin directly binds to and inhibits thrombin, a key enzyme in the coagulation cascade, preventing fibrin formation and clot propagation. Eptifibatide blocks the glycoprotein IIb/IIIa receptor on platelets, preventing platelet aggregation. Together, this combination provides comprehensive anticoagulation and antiplatelet effects for acute coronary syndromes and percutaneous coronary intervention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bivalirudin with and without eptifibatide

What is Bivalirudin with and without eptifibatide?

Bivalirudin with and without eptifibatide is a Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) drug developed by LifeBridge Health, indicated for Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.

How does Bivalirudin with and without eptifibatide work?

Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects.

What is Bivalirudin with and without eptifibatide used for?

Bivalirudin with and without eptifibatide is indicated for Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.

Who makes Bivalirudin with and without eptifibatide?

Bivalirudin with and without eptifibatide is developed and marketed by LifeBridge Health (see full LifeBridge Health pipeline at /company/lifebridge-health).

What drug class is Bivalirudin with and without eptifibatide in?

Bivalirudin with and without eptifibatide belongs to the Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) class. See all Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide) drugs at /class/direct-thrombin-inhibitor-bivalirudin-glycoprotein-iib-iiia-inhibitor-eptifibatide.

What development phase is Bivalirudin with and without eptifibatide in?

Bivalirudin with and without eptifibatide is FDA-approved (marketed).

What are the side effects of Bivalirudin with and without eptifibatide?

Common side effects of Bivalirudin with and without eptifibatide include Bleeding (major and minor), Thrombocytopenia, Hypotension, Bradycardia, Nausea.

What does Bivalirudin with and without eptifibatide target?

Bivalirudin with and without eptifibatide targets Thrombin (Factor IIa) and Glycoprotein IIb/IIIa receptor and is a Direct thrombin inhibitor (bivalirudin) + Glycoprotein IIb/IIIa inhibitor (eptifibatide).

Related